c-Met/HGFR
Les inhibiteurs de c-Met/HGFR ciblent le Récepteur du Facteur de Croissance des Hépatocytes (c-Met), une tyrosine kinase impliquée dans des processus cellulaires tels que la croissance, la motilité et la morphogenèse. La signalisation de c-Met est impliquée dans la progression du cancer, la métastase et la résistance aux thérapies. Inhiber c-Met peut perturber la croissance et la propagation des tumeurs, faisant de ces inhibiteurs des outils précieux dans la recherche sur le cancer. Chez CymitQuimica, nous proposons des inhibiteurs de c-Met/HGFR pour soutenir vos recherches en oncologie, métastase et thérapies ciblées contre le cancer.
142 produits trouvés pour "c-Met/HGFR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
BAY-474
CAS :BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probeFormule :C17H15N5Degré de pureté :98.98%Couleur et forme :SolidMasse moléculaire :289.33Ref: TM-T7900
1mg35,00€5mg71,00€10mg112,00€25mg203,00€50mg294,00€100mg411,00€200mg553,00€1mL*10mM (DMSO)84,00€Capmatinib 2HCl
CAS :Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.Formule :C23H19Cl2FN6ODegré de pureté :98.80%Couleur et forme :SolidMasse moléculaire :485.34Ref: TM-T4260
2mg34,00€5mg49,00€10mg64,00€25mg84,00€50mg92,00€100mg126,00€500mg303,00€1mL*10mM (DMSO)58,00€Ningetinib
CAS :Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Formule :C31H29FN4O5Degré de pureté :99.95% - 99.98%Couleur et forme :SolidMasse moléculaire :556.58SGX-523
CAS :SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
Formule :C18H13N7SDegré de pureté :99% - >99.99%Couleur et forme :SolidMasse moléculaire :359.41Pamufetinib mesylate
CAS :Pamufetinib mesylate (TAS-115 mesylate) is a VEGFR antagonist and c-Met inhibitor used in the study of cancer and respiratory diseases.Formule :C28H27FN4O7S2Degré de pureté :98.91%Couleur et forme :SolidMasse moléculaire :614.67Tivantinib
CAS :Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.Formule :C23H19N3O2Degré de pureté :98% - 99.41%Couleur et forme :SolidMasse moléculaire :369.42RPI-1
CAS :RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.Formule :C17H15NO4Degré de pureté :98.91% - ≥95%Couleur et forme :SolidMasse moléculaire :297.31Afatinib Dimaleate
CAS :Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the EGFR family, with antineoplastic activity.Formule :C32H33ClFN5O11Degré de pureté :98.11% - 99.87%Couleur et forme :SolidMasse moléculaire :718.08SGI-7079
CAS :SGI-7079: selective Axl inhibitor; hinders tumor growth dose-dependently; may target EGFR inhibitor resistance.Formule :C26H26FN7Degré de pureté :95.51% - 99.26%Couleur et forme :SolidMasse moléculaire :455.53Ref: TM-T6982
2mg39,00€5mg58,00€10mg92,00€25mg178,00€50mg230,00€100mg334,00€500mg782,00€1mL*10mM (DMSO)64,00€JNJ-38877605
CAS :JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.Formule :C19H13F2N7Degré de pureté :97.15% - 98.61%Couleur et forme :SolidMasse moléculaire :377.35Foretinib phosphate
CAS :Foretinib phosphate, an oral MET/VEGFR2 inhibitor GSK1363089, may curb tumor growth and spread.Formule :C34H40F2N4O14P2Couleur et forme :SolidMasse moléculaire :828.65S49076 HCl
CAS :S49076 HCl (S-49076 Hydrochloride) is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3.Formule :C22H18ClN3O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :439.85SAR125884 hydrochlorid (1116743-46-4(free base))
CAS :SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).Formule :C25H23FN8O2S2·HClDegré de pureté :97.95%Couleur et forme :SolidMasse moléculaire :587Ref: TM-T5677
1mg35,00€5mg57,00€10mg95,00€25mg178,00€50mg264,00€100mg374,00€200mg537,00€1mL*10mM (DMSO)96,00€PF-04217903
CAS :MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.Formule :C19H16N8ODegré de pureté :98.41% - 98.55%Couleur et forme :SolidMasse moléculaire :372.38NPS-1034
CAS :NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.Formule :C31H23F2N5O3Degré de pureté :98.48%Couleur et forme :SolidMasse moléculaire :551.54Ref: TM-T6907
1mg34,00€2mg46,00€5mg66,00€10mg92,00€25mg167,00€50mg245,00€100mg356,00€200mg530,00€1mL*10mM (DMSO)82,00€BMS-2
CAS :BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.Formule :C25H16F2N4O3Degré de pureté :98.33%Couleur et forme :SolidMasse moléculaire :458.42Ref: TM-T8326
1mg67,00€2mg88,00€5mg148,00€10mg230,00€25mg430,00€50mg622,00€100mg898,00€1mL*10mM (DMSO)170,00€XL092
CAS :XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
Formule :C29H25FN4O5Degré de pureté :98.60%Couleur et forme :SolidMasse moléculaire :528.53Capmatinib
CAS :Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Formule :C23H17FN6ODegré de pureté :99.24%Couleur et forme :SolidMasse moléculaire :412.42Ref: TM-T1963
5mg48,00€10mg63,00€25mg78,00€50mg90,00€100mg124,00€200mg158,00€500mg255,00€1mL*10mM (DMSO)50,00€PHA-665752
CAS :PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.Formule :C32H34Cl2N4O4SDegré de pureté :97.05% - 98.82%Couleur et forme :SolidMasse moléculaire :641.61CEP-40783
CAS :CEP-40783 (RXDX-106) is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).
Formule :C31H26F2N4O6Degré de pureté :99.76% - 99.84%Couleur et forme :SolidMasse moléculaire :588.56Ningetinib Tosylate
CAS :Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Formule :C38H37FN4O8SDegré de pureté :99.93%Couleur et forme :SolidMasse moléculaire :728.79Crizotinib
CAS :Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.Formule :C21H22Cl2FN5ODegré de pureté :99% - 99.87%Couleur et forme :SolidMasse moléculaire :450.34Ref: TM-T1661
2mgÀ demander5mg33,00€10mg49,00€25mg55,00€50mg64,00€100mg88,00€500mg147,00€1mL*10mM (DMSO)50,00€AMG-208
CAS :AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.Formule :C22H17N5O2Degré de pureté :98.56%Couleur et forme :SolidMasse moléculaire :383.4Altiratinib
CAS :Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Formule :C26H21F3N4O4Degré de pureté :99.67% - 99.75%Couleur et forme :SolidMasse moléculaire :510.46NVP-BVU972
CAS :NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.Formule :C20H16N6Degré de pureté :97.24% - >99.99%Couleur et forme :SolidMasse moléculaire :340.38Ref: TM-T2680
2mg44,00€5mg74,00€10mg97,00€25mg178,00€50mg255,00€100mg359,00€200mg510,00€1mL*10mM (DMSO)84,00€Hepln-13
CAS :Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.Formule :C17H13BrN2Degré de pureté :97.67%Couleur et forme :SolidMasse moléculaire :325.2Ref: TM-T25492
1mg35,00€2mg52,00€5mg80,00€10mg119,00€25mg231,00€50mg344,00€100mg480,00€200mg663,00€1mL*10mM (DMSO)92,00€BMS 777607
CAS :BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3. BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.Formule :C25H19ClF2N4O4Degré de pureté :98.89% - >99.99%Couleur et forme :SolidMasse moléculaire :512.89Ref: TM-T2699
1mg35,00€5mg79,00€10mg124,00€25mg217,00€50mg359,00€100mg533,00€500mg1.169,00€1mL*10mM (DMSO)92,00€MK-8033
CAS :MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).Formule :C25H21N5O3SDegré de pureté :97.16%Couleur et forme :SolidMasse moléculaire :471.53S49076
CAS :S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.Formule :C22H22N4O4SDegré de pureté :95.35% - 97.4%Couleur et forme :SolidMasse moléculaire :438.5Ref: TM-T3274
1mg34,00€2mg44,00€5mg58,00€10mg93,00€25mg167,00€50mg260,00€100mg432,00€200mg618,00€1mL*10mM (DMSO)64,00€Golvatinib
CAS :Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factorFormule :C33H37F2N7O4Degré de pureté :98.24% - ≥95%Couleur et forme :SolidMasse moléculaire :633.69Ref: TM-T6517
1mgÀ demander2mg46,00€5mg66,00€10mg92,00€25mg149,00€50mg197,00€100mg350,00€1mL*10mM (DMSO)À demanderAMG-337
CAS :AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).Formule :C23H22FN7O3Degré de pureté :99.26% - 99.9%Couleur et forme :SolidMasse moléculaire :463.46Ref: TM-T3209
1mg40,00€2mg52,00€5mg85,00€10mg124,00€25mg197,00€50mg350,00€100mg522,00€200mg748,00€1mL*10mM (DMSO)86,00€Glumetinib
CAS :Glumetinib (SCC244) (SCC 244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM).
Formule :C21H17N9O2SDegré de pureté :99.79%Couleur et forme :SolidMasse moléculaire :459.48DS-1205
CAS :DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.Formule :C41H42FN5O7Degré de pureté :99.75%Couleur et forme :SolidMasse moléculaire :735.8Capmatinib 2HCl.H2O
CAS :Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Formule :C23H21Cl2FN6O2Degré de pureté :99.77%Couleur et forme :SolidMasse moléculaire :503.36Ref: TM-T8825
2mg34,00€5mg48,00€10mg63,00€25mg84,00€50mg92,00€100mg126,00€500mg250,00€1mL*10mM (DMSO)50,00€Foretinib
CAS :Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.Formule :C34H34F2N4O6Degré de pureté :98.07% - 99.68%Couleur et forme :SolidMasse moléculaire :632.65Ref: TM-T3113
2mg39,00€5mg57,00€10mg79,00€25mg133,00€50mg207,00€100mg354,00€500mg848,00€1mL*10mM (DMSO)79,00€Amivantamab (Anti-c-MET)
CAS :Amivantamab (JNJ-61186372) is an antibody that recognizes EGFR and MET and has anticancer and antitumor activities.Degré de pureté :97.24% (SEC-HPLC) - >95.0% (SDS-PAGE); 99.74% (SEC-HPLC)Couleur et forme :LiquidMasse moléculaire :145.88 kDaDavutamig
CAS :Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.Degré de pureté :98%Couleur et forme :LiquidBafisontamab
CAS :Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].Couleur et forme :LiquidMAPK-IN-2
MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cellFormule :C20H11Cl2N3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :380.23BMS-754807
CAS :BMS-754807 is an oral IGF-1R/InsR inhibitor with potential anti-cancer properties.Formule :C23H24FN9ODegré de pureté :99.69% - 99.94%Couleur et forme :SolidMasse moléculaire :461.49Ref: TM-T2349
1mg50,00€2mg66,00€5mg90,00€10mg158,00€25mg310,00€50mg509,00€100mg732,00€1mL*10mM (DMSO)110,00€SU11274
CAS :SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.Formule :C28H30ClN5O4SDegré de pureté :98.62% - 99.53%Couleur et forme :Orange PowderMasse moléculaire :568.09Ref: TM-T6154
1mg44,00€2mg56,00€5mg92,00€10mg142,00€25mg268,00€50mg442,00€100mg652,00€1mL*10mM (DMSO)142,00€AMG-458
CAS :AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.Formule :C30H29N5O5Degré de pureté :99.91% - 99.98%Couleur et forme :SolidMasse moléculaire :539.58Glesatinib hydrochloride
CAS :Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO.Formule :C31H28ClF2N5O3S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :656.16Glesatinib
CAS :Glesatinib is an orally active and potent dual inhibitor of MET/SMO.Formule :C31H27F2N5O3S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :619.7AC-386
CAS :AC-386, a potent c-Met inhibitor (IC50 7.42 nM), inhibits cancer cell growth and aids anti-cancer resistance study.Formule :C35H34FN5O6Couleur et forme :SolidMasse moléculaire :639.67LCRF-0004
CAS :LCRF-0004 inhibits RON kinase, key in KRAS-driven pancreatic cancer, reducing cell migration and enhancing chemo sensitivity.Formule :C28H18F4N6O2SCouleur et forme :SolidMasse moléculaire :578.54c-Met-IN-11
CAS :c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).Formule :C30H20F2N4O3Couleur et forme :SolidMasse moléculaire :522.5Axl-IN-8
CAS :Axl-IN-8 (NO.1) is a potent inhibitor of AXL (IC50<1 nM) and also inhibits c-MET (IC50: 1-10 nM). : 120.3 nM).Formule :C31H29FN6O3Couleur et forme :SolidMasse moléculaire :552.6Mifanertinib
CAS :Mifanertinib is a potent tyrosine kinase inhibitor with antineoplastic activity .Formule :C21H19ClF3N5O2Couleur et forme :SolidMasse moléculaire :465.86c-Met-IN-16
CAS :c-Met-IN-16 is a c-Met inhibitor that can be used for cancer research .Formule :C21H17F2N9OCouleur et forme :SolidMasse moléculaire :449.42
